Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01498640 · ClinicalTrials.gov registry record · Phase 4
Retreatment of Recurrent Dupuytren's Contractures
A Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT01498640: Completed Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT01498640 is a Phase 4 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 52 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01498640, a Phase 4 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
The objectives of this study are to assess the safety and efficacy of AA4500 in the retreatment of recurrent contractures in joints that were effectively treated with AA4500 in a previous Auxilium-sponsored Phase 3 study.
Primary Outcome
Clinical success defined as reduction in fixed-flexion contracture to less than or equal to 5 degrees 30 days after the last injection of AA4500
Interventions
- BIOLOGICAL Collagenase clostridium histolyticum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-10 |
| Phase | Phase 4 |
What the finished NCT01498640 record still lists
NCT01498640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Collagenase clostridium histolyticum is the first listed.
NCT01498640 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01498640 about?
NCT01498640 is a clinical study titled "Retreatment of Recurrent Dupuytren's Contractures". The objectives of this study are to assess the safety and efficacy of AA4500 in the retreatment of recurrent contractures in joints that were effectively treated with AA4500 in a previous Auxilium-sponsored Phase 3 study.
What is the current status of trial NCT01498640?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2012-03. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01498640?
The interventions under investigation include: Collagenase clostridium histolyticum (BIOLOGICAL).
Who is sponsoring clinical trial NCT01498640?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01498640's enrollment target sits among peer trials
52 1233rd of 2000 higher than 752 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia